Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Pioneering
personalized medicine
in epigenetics

Oryzon now

18 January 2023

ORYZON announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas

Read more
5 January 2023

ORYZON to give updates on corporate progress in January

Read more
16 December 2022

ORYZON awarded EU grant to further explore the role of iadademstat in oncological immunotherapy approaches

Read more

ORYZON is a public clinical stage biopharmaceutical company developing innovative epigenetic personalized medicines for patients with cancer and CNS disorders

About us
Epigenetics

Epigenetics is a regulatory system that controls gene expression without affecting the makeup of the genes themselves. Regulation of gene transcription and translation are key biological determinants for cellular differentiation and function, and transcriptional imbalances play a significant pathogenic role in a number of human diseases.

More info
Therapeutic programs

ORYZON is a clinical stage biopharmaceutical company that leverages epigenetics to discover and develop innovative personalized therapeutics for patients with cancers and CNS disorders. We are able to identify and validate biomarkers and therapeutic targets through our epigenetic platform and translate them into advanced and personalized therapies.

More info
Latest News
  • 18 January 2023

    ORYZON announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas

    • Read more about ORYZON announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas
  • 5 January 2023

    ORYZON to give updates on corporate progress in January

    • Read more about ORYZON to give updates on corporate progress in January
  • 16 December 2022

    ORYZON awarded EU grant to further explore the role of iadademstat in oncological immunotherapy approaches

    • Read more about ORYZON awarded EU grant to further explore the role of iadademstat in oncological immunotherapy approaches
All News
Upcoming events
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy